top stories

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

9 hours ago
R&D

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of ...

Yesterday
R&D

As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

7 hours ago
R&D

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

3 hours ago
R&D
Regulatory

Latest

Most read

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try ...

Yesterday
People
R&D

Once a gem, now just a rock, Take­da punts PhI­II IBD drug as ri­vals mus­cle ahead

7 hours ago
R&D

Min­er­va suf­fers an­oth­er CNS de­feat; Eli Lil­ly wins OK for tau-based Alzheimer's di­ag­nos­tic

7 hours ago
Protocols

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

7 hours ago
Peer Review

Ear­ly sur­vival da­ta boost Zio­phar­m's 'con­trolled IL-12' im­munother­a­py for glioblas­toma

7 hours ago
R&D
Cell/Gene Tx

As tislelizum­ab gains trac­tion in Chi­na, BeiGene pulls the cur­tain on NSCLC da­ta sup­port­ing the PD-1 drug

8 hours ago
R&D
China
see latest stream
People

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

10 hours ago

Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

10 hours ago

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few ...

Yesterday
Startups

For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

2 days ago

Daphne Koller’s AI start­up gets $143M in new cash from a16z, oth­ers

3 days ago

Be­zos, Paul Allen funds, a16z put up $100M to build an Il­lu­mi­na of hu­man pro­teins

Last week
Deals

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

2 days ago

In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

2 days ago

PhII Alzheimer's da­ta loom­ing, Sh­iono­gi spend­ing up to $500M on a buy­out in­volv­ing one of the tough­est bets in ...

3 days ago
IPOs

As biotech IPOs siz­zle on vir­tu­al Wall Street, 3 new play­ers roll the dice on meg­a­money gam­bles top­ping $325M

3 days ago

A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

Last week

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots ...

4 weeks ago
Bioregnum
R&D

Deal­mak­ing spiked to record lev­els in April as Covid-19 trig­gered a fever of part­ner­ing. But what hap­pens to ...

4 weeks ago
Deals

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare ...

5 weeks ago
Bioregnum
R&D

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

Last month
Bioregnum
R&D

Don't missSee all

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

Yesterday
Coronavirus

Covid-19 roundup: FDA's Stephen Hahn per­son­al­ly helped a doc­tor set up hy­drox­y­chloro­quine tri­al — re­port

Yesterday
Coronavirus

Stymied by the pan­dem­ic, Im­munomedic­s' new CEO bows out, tak­ing a mil­lion bucks plus perks as he heads out the ...

2 days ago
People

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

2 days ago
Bioregnum
R&D

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

Last month
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

6 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

7 months ago

Peer review See all

May
22

The man who led Gilead’s au­toim­mune piv­ot heads to Boston; No­var­tis gets a new chief for its AI In­no­va­tion Cen­ter

May
15

Cher­ry Thomas joins Cari­bou as SVP of clin­i­cal de­vel­op­ment; Ar­tax locks in Joseph Lobac­ki as CEO

May
8

Ex-As­traZeneca ex­ec Kris­ten Buck hops aboard Icon as CMO; Im­muno­core taps Bri­an Di­Do­na­to as CFO

May
1

High-pro­file R&D spe­cial­ist David Leb­wohl jumps to new job as CMO of a pi­o­neer­ing CRISPR play­er; Trou­bled AM­AG ...

Apr
24

Lau­ra Shawver on why she came back af­ter an $88M wind­fall; Mor­phoSys taps Am­gen vet as CCO

R&D channel feed

3 days ago

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Mer­ck ex­ecs are mak­ing a triple play in a sud­den leap in­to the R&D cam­paign against Covid-19. And they have more BAR­DA cash back­ing them up on the move. Tues­day morn­ing the phar­ma ...

READ MORE

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

Yesterday
Coronavirus

Al­ny­lam nabs speedy re­view, set­ting up 3rd pos­si­ble ap­proval in 3 years

3 days ago
Regulatory
latest in R&D

Ku­ra flash­es pos­i­tive HRAS da­ta on once-failed J&J drug

8 hours ago

Af­ter star­ring at ASH last fall, Gilead’s new Forty Sev­en crew col­ors in more promis­ing da­ta for ma­grolimab at AS­CO

8 hours ago

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

10 hours ago
Pharma

Iron­wood, Ab­b­Vie kick de­layed-re­lease Linzess for­mu­la­tion to the curb af­ter tri­al fail­ure

11 hours ago

In for the long vac­cine game, Mer­ck buys in­to patch de­liv­ery tech with pan­dem­ic po­ten­tial

Yesterday
see latest stories

Pharma channel feed

2 days ago

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

Bris­tol My­ers Squibb may be trail­ing Mer­ck and Roche in the check­point race to treat front­line cas­es of non-small cell lung can­cer, but as it does, it makes sure to bring its best feet ...

READ MORE

Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

Last week

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

Last week
Regulatory
latest in Pharma

Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ap­proval

Last week
Regulatory

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

Last week
Regulatory

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

Last week
Regulatory

Bris­tol My­ers Squibb spells out OS ben­e­fit of Op­di­vo/Yer­voy com­bo plus 'lim­it­ed' chemother­a­py — is it enough to change prac­tice?

3 weeks ago
R&D

As­traZeneca, Mer­ck­'s star PARP in­hibitor Lyn­parza ex­pands reach in ovar­i­an can­cer with new US ap­proval

3 weeks ago
Regulatory
see latest stories

Coronavirus channel feed

2 days ago

Covid-19 roundup: Buoyed by soar­ing shares, No­vavax inks a $167M deal to buy Covid-19 vac­cine-mak­ing fa­cil­i­ty; France cools on hy­drox­y­chloro­quine

The pan­dem­ic has of­fered the best news No­vavax has had in years. Its stock price is trad­ing at 7x the pre-pan­ic lev­els with a Covid-19 vac­cine in the mix, as in­vestors buy any­thing that ...

READ MORE

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

3 days ago
Biotech Voices

Covid-19 roundup: Jun­shi, Eli Lil­ly ready to launch Covid-19 an­ti­body tri­al; Janet Wood­cock steps aside — for now ...

3 days ago
latest in Coronavirus

FDA ex­plains im­pact of Covid-19 on ap­pli­ca­tions, for­mal meet­ings

Yesterday
Regulatory

Re­searchers de­fine ex­act­ly what they saw in the first pos­i­tive remde­sivir study for Covid-19. But what's that worth to Gilead?

6 days ago
Bioregnum

Covid-19 roundup: CanSi­no beats Mod­er­na to pub­li­ca­tion of first-in-hu­man da­ta for a coro­n­avirus vac­cine

Last week

EMA ex­tends vir­tu­al-on­ly meet­ing pol­i­cy through Au­gust

Last week
Regulatory

Covid-19 roundup: BAR­DA hands As­traZeneca $1B-plus to race through PhI­II and ramp up fall de­liv­er­ies of Ox­ford’s pan­dem­ic vac­cine

Last week
see latest stories